Market news

Motley Fool Press Release.

Moby summary of Harvard Bioscience, Inc.'s Q2 2026 earnings call

Harvard Bioscience Inc. (NASDAQ:HBIO) reported better-than-expected second-quarter results on Tuesday and raised its full-year 2026 revenue outlook after stronger demand across its telemetry and cellular and molecular technology businesses.

Second Quarter 2026 Revenue Growth of 11% Year Over Year to $22.7 Million Raises Full Year 2026 Revenue Guidance to 3%-5% Year Over Year Growth HOLLISTON, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced financial results for the second quarter ended June 30, 2026. "We delivered a strong quarter anchored by 11% top-line growth, reflective of stronger demand and an improved environment across our key customer

Harvard Bioscience: Q2 Earnings Snapshot

Strong Q2 performance driven by robust demand in China and new product adoption, prompting an upward revision to full-year revenue growth outlook.